Format

Send to

Choose Destination
Am J Hematol. 2017 Mar;92(3):317-321. doi: 10.1002/ajh.24648. Epub 2017 Feb 3.

Diagnostic work-up of acute myeloid leukemia.

Author information

1
Department of Pathology, Boston Children's Hospital, Boston, Massachusetts.
2
Department of Pathology, Harvard Medical School, Boston, Massachusetts.
3
Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
4
Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Abstract

Acute myeloid leukemia (AML) is characterized by a clonal expansion of undifferentiated myeloid precursors resulting in impaired hematopoiesis and bone marrow failure. In 2016, the World Health Organization (WHO) published revisions to the classification of myeloid neoplasms and acute leukemias. Similar to the 2008 classification, the updated classification incorporates clinical features, morphology, immunophenotyping, and cytogenetics, with greater emphasis on molecular genetics, to define disease entities. This brief review addresses the various components of pathologic assessment to establish a diagnosis of AML and to help risk stratify patients, with an emphasis on newer techniques used in the detection of mutations with prognostic significance, as well as assays employed in the evaluation of minimal residual disease following treatment.

PMID:
28066929
DOI:
10.1002/ajh.24648
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center